<DOC>
	<DOCNO>NCT02612857</DOCNO>
	<brief_summary>The purpose study determine safe effective IMO-8400 adult dermatomyositis .</brief_summary>
	<brief_title>Trial IMO-8400 Adult Patients With Dermatomyositis</brief_title>
	<detailed_description>This study evaluate safety efficacy IMO-8400 adult active dermatomyositis ( DM ) .</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<criteria>Has definite probable DM base criterion Bohan Peter Has Cutaneous Dermatomyositis Disease Area Severity Index ( CDASI ) Activity score â‰¥15 Patients muscle weakness eligible ; however muscle weakness mandatory . Study participant must diagnostic evaluation cancer diagnosis DM within 2 year prior Screening Visit Has ongoing severe dysphagia ( e.g. , require feed tube ) 3 month prior Screening Has know hypersensitivity oligodeoxynucleotide Has history drug alcohol abuse within one year screening , evidence drug abuse urine drug screening Has body weight &gt; 140 kg Has diagnosis Juvenile DM , IBM , druginduced toxic myopathy , metabolic myopathy , dystrophy , cancerassociated DM , connective tissue diseaseassociated DM ( e.g. , overlap syndrome ) Has receive one follow prohibit treatment within interval note prior Screening ( Visit 1 ) : 1 . Rituximab within 24 week ( Note : patient receive rituximab eligible inclusion Bcell count confirm within normal limit ) 2 . Intravenous corticosteroid within 12 week 3 . Antimalarials ( e.g. , hydroxychloroquine ) within 36 week 4 . Topical corticosteroid ( exclude scalp ) within 2 week Has evidence require treatment cancer ( except treat , noninvasive carcinoma skin cure cervical carcinomainsitu ) within 5 year Has interstitial lung disease require use supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dermatomyositis</keyword>
	<keyword>IMO-8400</keyword>
	<keyword>Pioneer</keyword>
</DOC>